Methylomics is a cancer diagnostics company that specializes in cancer diagnosis and monitoring by genome wide methylation profiling. A unique and inexpensive technique called MeD-seq, developed by the founders of Methylomics, helped us to create the extensive DNA methylation cancer atlas, Methyl-Me. Methyl-Me consists of MeD-seq, a database and AI algorithm and can be used for diagnosis, treatment monitoring and determining the origin of the tumor. The MeD-seq technology also helped us discover two proprietary pan-gynecological markers that can be used for the rapid detection of all types of gynecological cancers at once with our MeD-Scan assay.
๐๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ
โข Methylation profiling and marker discovery: Partner with us on innovative research projects and explore the diagnostic potential of methylation markers.
โข Diagnostic assay development service: Collaborate with our experts to develop rapid and inexpensive methylation assays for the detection of specific cancer types.
โข Clinical trials: Join forces in conducting clinical trials. Strengthen the
clinical utility of methylation sequencing in personalized medicine for diagnosis & treatment monitoring of cancers and other diseases.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Visseringlaan 25, Rijswijk,south Holland 2288,netherlands
- Industry
- Biotechnology
- Website
- methylomics.nl
- HQ
- Rijswijk, South Holland
Methylomics Questions
Methylomics's website is methylomics.nl
Methylomics's LinkedIn profile is https://nl.linkedin.com/company/methylomics
Methylomics has
6 employees.
View email and phone details for 6
employees at Methylomics.
Methylomics's industry is
Biotechnology
Methylomics's top competitors are
Leiden Bio Science Park,
Cellpoint,
Genomescan,
Tno,
Element Biosciences,
Maptimmune,
Comfycoders,
Oxford Nanopore Technologies,
Historical Microscopy Foundation (Stichting Historische Microscopie),
Hal Allergy Group.
Methylomics's categories are Biotechnology
Methylomics's founding year is 2018
